Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Martin Kortüm

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Blood|December 2, 2017
First targeted therapy in multiple myelomaK Martin Kortüm, Hermann Einsele
Blood|April 10, 2025
sBCMA and MTV prediction of outcome for CARTHermann Einsele, K Martin Kortüm
Cancer Cell|November 12, 2015
SnapShot: Multiple MyelomaEsteban Braggio, K Martin Kortüm, A Keith Stewart
Haematologica|February 15, 2024
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossibleMonika Engelhardt, K Martin Kortüm, Hartmut Goldschmidt, et al.
International Journal of Molecular Sciences|March 16, 2019
The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple MyelomaLeo Rasche, K Martin Kortüm, Marc S Raab, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 15, 2024
Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future PerspectivesJohannes M Waldschmidt, Leo Rasche, K Martin Kortüm, et al.
Haematologica|October 20, 2022
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practiceXiang Zhou, Leo Rasche, K Martin Kortüm, et al.
Bone Marrow Transplantation|August 22, 2019
The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCTHermann Einsele, Leo Rasche, Max S Topp, et al.
Frontiers in Immunology|January 11, 2021
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management StrategiesXiang Zhou, Leo Rasche, K Martin Kortüm, et al.
Leukemia & Lymphoma|July 19, 2019
Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donorPatrick-Pascal Strunz, Marc Schmalzing, Anke Heidemeier, et al.
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Blood|December 2, 2017
First targeted therapy in multiple myelomaK Martin Kortüm, Hermann Einsele
Blood|April 10, 2025
sBCMA and MTV prediction of outcome for CARTHermann Einsele, K Martin Kortüm
Cancer Cell|November 12, 2015
SnapShot: Multiple MyelomaEsteban Braggio, K Martin Kortüm, A Keith Stewart
Haematologica|February 15, 2024
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossibleMonika Engelhardt, K Martin Kortüm, Hartmut Goldschmidt, et al.
International Journal of Molecular Sciences|March 16, 2019
The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple MyelomaLeo Rasche, K Martin Kortüm, Marc S Raab, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 15, 2024
Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future PerspectivesJohannes M Waldschmidt, Leo Rasche, K Martin Kortüm, et al.
Haematologica|October 20, 2022
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practiceXiang Zhou, Leo Rasche, K Martin Kortüm, et al.
Bone Marrow Transplantation|August 22, 2019
The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCTHermann Einsele, Leo Rasche, Max S Topp, et al.
Frontiers in Immunology|January 11, 2021
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management StrategiesXiang Zhou, Leo Rasche, K Martin Kortüm, et al.
Leukemia & Lymphoma|July 19, 2019
Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donorPatrick-Pascal Strunz, Marc Schmalzing, Anke Heidemeier, et al.
Pageof 10